Ever since injections promising to help people lose weight hit the shelves, interest around the world has been phenomenal. So high was demand, companies were finding it difficult to keep up with the demand.
The pharma firm has announced the agency has approved the company’s investigational new drug application for its Phase II trial of pemvidutide for obesity.
The pharmaceutical company has announced GMP-related challenges with a manufacturer contracted to fill syringes for Wegovy pens headed to the US market.
The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.
The virtual clinical development firm’s analysis of patient profiles reflects obesity is the most significant indicator for severity in those under 40.
The pharmacy company's Wegovy (semaglutide) is the first therapy designated for chronic weight management that the agency has granted approval since 2014.
Following an €8M Series A fundraising round by Eternygen GmBh, the German CRO Evotec AG will help get the virtual biotech’s metabolic disease inhibitor programme to preclinical trials.
Amgen has retracted a study showing how grizzly bears could hold the key to understanding diabetes after one of the authors was found to have manipulated data.
Approval of Qsymia - Vivus’ anti-obesity drug – may be good news for the 35 per cent of US citizens classed as obese, but it is definitely good news for Taiwan-based CMO ScinoPharm.
Patient recruitment specialist Acurian has hit a major milestone in its business, with more than half of the entire US population of type 2 diabetics now opted into its database.
Boehringer Ingelheim has witnessed Vitae Pharmaceuticals attack the
same diabetes and obesity target as itself, only faster, and has
decided to splash out for a piece of the action.
Drug developers have a new target to aim at in the fight against
obesity after the discovery that a certain protein in the body
stimulates the formation of fat cells.
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Sanofi-Aventis' hotly touted anti-obesity blockbuster drug has
become weighted down in safety concerns as the French company
withdraws its New Drug Application (NDA) in the US and awaits a
safety review in the EU.
A molecule that links spontaneous physical activity such as
fidgeting and food intake could be a promising new target for drugs
to control diet-induced obesity, researchers from Europe and the US
suggest.
A chewing gum to treat Type 2 diabetes and obesity is one step
closer to reality after developers of the technology, Generex,
formed a new partnership with Danish medicinal chewing gum
specialists, Fertin Pharma, to develop the product.
Biotechnology company, Amgen, and Biovitrum have expanded its
existing license agreement for its treatment of metabolic
disorders, focusing on type 2 diabetes, which currently afflicts
over 160 million people worldwide.
Buccal drug delivery pioneer, Generex, is expanding its diabetes
treatment pipeline to include a new metformin chewing gum that aims
to avoid the significant adverse gastrointestinal side-effects
often accompanying the use of metformin...
Coremed has introduced its proprietary drug-delivery platform
technology that improves absorption of certain proteins and
macromolecules such as insulin within the gastrointestinal tract.
The FDA is to extend its original review period for Exubera
(insulin (rDNA origin) powder for oral inhalation) by three months
to review additional technical chemistry data submitted by its
producers.
A patent has been issued to Arena Pharmaceuticals for its small
molecule treatment for obesity, which targets a specific receptor,
thought to be involved in the regulation of food intake and may be
useful in pharmaceutical compositions...
Pharmaceutical giants Johnson and Johnson announced today it is to
discontinue its current clinical development program for its
controlled release formulation of topiramate in obesity after
studies revealed the formulation did not...
A new approach to treating obesity which blocks brain signals that
control cravings has shown promising results in human subjects
during advanced clinical trials paving the way for further testing
and an eventual launch date.
Research into obesity treatment and its related disorders took
another step forward after two studies isolated drug targets that
could prove effective for the millions who suffer from
obesity-related problems.
Researchers have isolated a protein that appears to be behind the
curious phenomenon that severe dietary restruction can extend the
lifespan of some organisms. The protein is thought to control
whether a mammal stores fat or sheds...
A new approach to treating obesity that destroys fat tissue using a
targeted peptide drug has shown promising results in mice and will
move on to non-human primate studies this summer, reports Phil
Taylor.
A new activity-based proteomics screening technique has allowed
scientists to identify active targets and simultaneously screen for
their inhibitors. The screening technique has already revealed that
orlistat, an anti-obesity drug,...
The European Commission has launched a five-year €11.7 project to
identify brain mechanisms affecting obesity and seek new treatments
to treat the condition.
